ArticleNutrients2021
The Homocysteine and Metabolic Syndrome: A Mendelian Randomization Study.
Article in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Association of methylenetetrahydrofolate reductase C677T polymorphism with lacunar infarction: A systematic review and meta-analysis.Medicine · 2026Pooled it
- Vitamin B12, folate, and homocysteine in metabolic syndrome: a systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Longitudinal Study of Plasma Metabolites During Menopause and Their Associations With Later Onset of Metabolic Syndrome.The Journal of clinical endocrinology and metabolism · 2026Article
- The causal role of homocysteine in multiple diseases: a systematic review of Mendelian randomization studies.Nutrition & metabolism · 2025Review
- Associations of Circulating Biomarkers with Disease Risks: A Two-Sample Mendelian Randomization Study.International journal of molecular sciences · 2024Article
- Associations of Circulating Biomarkers with Disease Risks: a Two-Sample Mendelian Randomization Study.medRxiv : the preprint server for health sciences · 2024Article
- Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome.Frontiers in pharmacology · 2024Review
- Metabolic disorders and risk of cardiovascular diseases: a two-sample mendelian randomization study.BMC cardiovascular disorders · 2023Article
- Article
- Associations of non-traditional cardiovascular risk factors and body mass index with metabolic syndrome in the Chinese elderly population.Diabetology & metabolic syndrome · 2023Article
- Habitual Tea Consumption Increases the Incidence of Metabolic Syndrome in Middle-Aged and Older Individuals.Nutrients · 2023Article
- Mendelian randomization study to investigate the causal relationship between plasma homocysteine and chronic obstructive pulmonary disease.World journal of emergency medicine · 2023Article
- Increased serum homocysteine in first episode and drug-naïve individuals with schizophrenia: sex differences and correlations with clinical symptoms.BMC psychiatry · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Homocysteine (Hcy) is well known to be increased in the metabolic syndrome (MetS) incidence. However, it remains unclear whether the relationship is causal or not. Recently, Mendelian Randomization (MR) has been popularly used to assess the causal influence. In this study, we adopted MR to investigate the causal influence of Hcy on MetS in adults using three independent cohorts. We considered one-sample MR and two-sample MR. We analyzed one-sample MR in 5902 individuals (2090 MetS cases and 3812 controls) from the KARE and two-sample MR from the HEXA (676 cases and 3017 controls) and CAVAS (1052 cases and 764 controls) datasets to evaluate whether genetically increased Hcy level influences the risk of MetS. In observation studies, the odds of MetS increased with higher Hcy concentrations (odds ratio (OR) 1.17, 95%CI 1.12-1.22,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.